BioPharma Resources

Investigational drug · Phase 3

AK117

Not approved by FDA. In 14 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes.

Phase 3

Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

14

12 still active

All registered trials

19

Any phase or sponsor naming "AK117"

First trial start

2021

Jun 18, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AK117", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Malignant Tumors
  • ACUTE MYELOID LEUKEMIA; AML
  • Higher-risk Myelodysplastic Syndromes
  • Metastatic Colorectal Cancer
  • Acute Myeloid Leukemia
  • Pancreatic Cancer
  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)
  • Head and Neck Squamous Cell Carcinoma
  • Metastatic Triple-negative Breast Cancer
  • Locally Advanced Triple-negative Breast Cancer

Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Head and neck cancer · Acute myeloid leukemia · Oncology · Hematology and blood cancers · Rare and genetic disease · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "AK117" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Advanced Malignant Tumors

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • JSKN033Phase 34 trials

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors

  • IAP0971Phase 23 trials

    SUNHO(China)BioPharmaceutical CO., Ltd. · Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer

  • IBB0979Phase 22 trials

    SUNHO(China)BioPharmaceutical CO., Ltd. · Small Cell Lung Cancer, Advanced Malignant Tumors

  • JMT108Phase 22 trials

    Shanghai JMT-Bio Inc. · Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors, Advanced Malignant Tumors

  • LBL-033Phase 21 trial

    Nanjing Leads Biolabs Co.,Ltd · Advanced Malignant Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.